Table 1.
Demographic characteristics, drug use and number of prescriptions for pharmacogenomics (PGx) targets.
| Total | Age Groups (Year) | |||
|---|---|---|---|---|
| 65–74 | 75–84 | 85–98 | ||
| No. of residents. | 141 | 22 (15.6) | 51 (36.2) | 68 (48.2) |
| No. of female gender | 80 (56.7) | 13 | 31 | 36 |
| Mean no. of drugs | 12.0 | 12.2 | 13.0 | 11.5 |
| No. of prescriptions (PGx-target) | ||||
| CYP2C19 (AG/N-AG) | 133/3 | 23/1 | 59/1 | 51/1 |
| CYP2D6 (AG/N-AG) | 54/75 | 8/16 | 16/26 | 30/33 |
| CYP2C9 (AG/N-AG) | 3/0 | 0/0 | 1/0 | 2/0 |
| SLCO1B1 (AG/N-AG) | 42/0 | 9/0 | 23/0 | 10/0 |
| Total for PGx targets (AG/N-AG) | 232/78 | 40/17 | 99/27 | 93/34 |
Numbers in brackets are percentage expressed relative to total No. of residents. AG: actionable guidelines and N-AG: non-actionable guidelines. The total no of prescriptions in each PGx-target category is the sum of AG + N-AG i.e., total for PGx targets are 232 + 78 = 310 prescriptions.